동물용 백신 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 동물별, 투여 경로별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Animal Vaccines Market Summary

The global animal vaccines market size was estimated at USD 14.8 billion in 2025 and is projected to reach USD 32.4 billion by 2033, growing at a CAGR of 10.5% from 2026 to 2033. Some of the factors driving market growth are increasing cattle disease outbreaks, rising advancements in innovative therapies, and growing emphasis on the One Health approach & zoonotic disease prevention.

The increasing frequency and severity of livestock disease outbreaks are significantly driving demand for animal vaccines globally. Some of the diseases, such as foot-and-mouth disease (FMD), avian influenza, African swine fever, and lumpy skin disease, have led to substantial economic losses and disruptions in food supply chains. According to a report, African Swine Fever caused over USD112.5 billion in losses during 2019, while Foot-and-Mouth Disease results in annual losses of USD21 billion, highlighting the significant economic burden of livestock diseases globally. In addition, governments and international organizations are implementing large-scale immunization programs to control outbreaks and prevent cross-border disease transmission. In addition, rising global trade of livestock products has increased the need for stringent biosecurity and vaccination protocols. This trend is particularly prominent in developing economies, where livestock farming is a critical source of livelihood.

In addition, the emergence of mRNA and next-generation vaccine technologies is transforming the market by enabling faster, more efficient, and targeted vaccine development. These mRNA-based platforms allow rapid design and scalability, making them highly effective in responding to emerging and mutating pathogens, unlike traditional vaccines. For instance, in July 2025, an mRNA FMD vaccine was developed with Friedrich-Loeffler-Institut that demonstrated full protection in cattle and reduced virus transmission, highlighting its effectiveness and advantages over traditional vaccine production methods. These advanced vaccines offer improved safety profiles and enhanced immune responses across companion and livestock animals. In addition, biopharmaceutical companies are investing in RNA-based, recombinant, and vector-based vaccines in large numbers to address complex and previously unmet veterinary needs. Furthermore, the integration of advanced manufacturing technologies supports large-scale production and commercialization.

Furthermore, growing emphasis on the One Health approach, which integrates human, animal, and environmental health, is a key market driver. Many of the emerging infectious diseases are zoonotic in nature, and preventing disease transmission from animals to humans has become a global priority. According to the CDC report of April 2025, scientists estimated more than 60% of known human infectious diseases originate from animals, whereas about 75% of emerging infections are zoonotic, highlighting the critical role of animal health management and vaccination. Thus, vaccination of animals plays a crucial role in reducing the risk of zoonotic outbreaks, safeguarding public health, and minimizing economic losses. In addition, governments, health organizations, and veterinary stakeholders are collaborating in large numbers to implement comprehensive immunization strategies and surveillance systems. For instance, in August 2025, the Pirbright Institute and CPI partnered to advance RNA livestock vaccines, accelerating innovation, scalable production, and rapid disease response capabilities. As awareness and regulatory support increase, the focus on preventive animal healthcare is strengthening, thereby driving sustained demand for vaccines.

Global Animal Vaccines Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global animal vaccines market report based on product, animal, route of administration, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Attenuated Live Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• DNA & RNA Vaccines
• Recombinant Vaccines
• Autologous Vaccines
• Other Vaccines
• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Livestock
  • Poultry
  • Aqua
  • Ruminants
  • Swine
• Companion
  • Canine
  • Feline
  • Equine
  • Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Injectable
  • Subcutaneous
  • Intramuscular
  • Intradermal
  • Intraperitoneal
• Oral
• Other Routes
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail
• E-Commerce
• Hospital/ Clinic Pharmacy
• Veterinary Supply Distributors
• Other Channels
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Animal
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1: Commodity Flow Analysis
  • 1.7.2. Model 2: Bottom-Up Analysis
  • 1.7.3. Model 3 Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Cattle Disease Outbreaks
    • 3.2.1.2. Rising Advancements in Innovative Therapies
    • 3.2.1.3. Growing Emphasis on the One Health Approach & Zoonotic Disease Prevention
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Cost of Vaccine Development and Production
    • 3.2.2.2. Stringent Regulatory Approval Processes
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Estimated Animal Population by Key Species & Key Countries, 2025
• 3.4. Product Pipeline Analysis
• 3.5. Pricing Analysis
• 3.6. Disease Outbreak Analysis
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Forces Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Animal Vaccines Market: By Product Estimates & Trend Analysis

• 4.1. Animal Vaccines Market, By Product: Segment Dashboard
• 4.2. Animal Vaccines Market, By Product Movement Analysis
• 4.3. Animal Vaccines Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
• 4.4. Attenuated Live Vaccines
  • 4.4.1. Attenuated Live Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Inactivated Vaccines
  • 4.5.1. Inactivated Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Subunit Vaccines
  • 4.6.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. DNA & RNA Vaccines
  • 4.7.1. DNA & RNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Recombinant Vaccines
  • 4.8.1. Recombinant Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Autologous Vaccines
  • 4.9.1. Autologous Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.10. Other Vaccines
  • 4.10.1. Other Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Animal Vaccines Market: By Animal Estimates & Trend Analysis

• 5.1. Animal Vaccines Market, By Animal: Segment Dashboard
• 5.2. Animal Vaccines Market, By Animal Movement Analysis
• 5.3. Animal Vaccines Market Estimates & Forecasts, by Animal, 2021 to 2033 (USD Million)
• 5.4. Livestock
  • 5.4.1. Livestock Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Poultry
    • 5.4.2.1. Poultry Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Aqua
    • 5.4.3.1. Aqua Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Ruminants
    • 5.4.4.1. Ruminants Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.5. Swine
    • 5.4.5.1. Swine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Companion
  • 5.5.1. Companion Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Canine
    • 5.5.2.1. Canine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Feline
    • 5.5.3.1. Feline Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. Equine
    • 5.5.4.1. Equine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Others
    • 5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Animal Vaccines Market: By Route of Administration Estimates & Trend Analysis

• 6.1. Animal Vaccines Market, By Route of Administration: Segment Dashboard
• 6.2. Animal Vaccines Market, By Route of Administration Movement Analysis
• 6.3. Animal Vaccines Market Estimates & Forecasts, by Route of Administration, 2021 to 2033 (USD Million)
• 6.4. Injectable
  • 6.4.1. Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Subcutaneous
    • 6.4.2.1. Subcutaneous Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Intramuscular
    • 6.4.3.1. Intramuscular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Intradermal
    • 6.4.4.1. Intradermal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Intraperitoneal
    • 6.4.5.1. Intraperitoneal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Oral
  • 6.5.1. Oral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Other Routes
  • 6.6.1. Other Routes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Animal Vaccines Market: By Distribution Channel Estimates & Trend Analysis

• 7.1. Animal Vaccines Market, By Distribution Channel: Segment Dashboard
• 7.2. Animal Vaccines Market, By Distribution Channel Movement Analysis
• 7.3. Animal Vaccines Market Estimates & Forecasts, by Distribution Channel, 2021 to 2033 (USD Million)
• 7.4. Retail
  • 7.4.1. Retail Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. E-Commerce
  • 7.5.1. E-Commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Hospital/ Clinic Pharmacy
  • 7.6.1. Hospital/ Clinic Pharmacy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Veterinary Supply Distributors
  • 7.7.1. Veterinary Supply Distributors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Other Channels
  • 7.8.1. Other Channels Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Animal Vaccines Market: By Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Zoetis
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Merck & Co., Inc.
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Boehringer Ingelheim Animal Health
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Elanco
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Virbac
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Phibro Animal Health Corporation
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Calier
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Ceva
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Bimeda Biologicals
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Neogen Corporation
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives